Pharmaceuticals For Rare Diseases will Continue to Thrive in China

In 2020, the Chinese NMPA established the Rare Diseases Registry. Since then, more foreign and local drug companies have been interested in getting their rare disease drugs into China. According to GlobalData’s Drugs Intelligence Database, there are now 378 drugs for rare diseases in development in China, with over half of them in at least Phase 2 development. China approved 11 rare disease drugs to date in 2022 with more in the pipeline. As mentioned in our earlier news briefs, China’s NMPA is now favoring rare disease and pediatric drugs with faster review times.

Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.

Source used in the article: